Table of contents

Clinical and epidemiological research

• Extended report: Comparison of the American-European Consensus Group Sjögren's syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised sicca cohort (22 August, 2013) Free

  Astrid Rasmussen, John A Ice, He Li, Kiely Grundahl, Jennifer A Kelly, Lida Radfar, Donald U Stone, Kimberly S Hefner, Juan-Manuel Anaya, Michael Rohrer, Rajaram Gopalakrishnan, Glen D Houston, David M Lewis, James Chodosh, John B Harley, Pamela Hughes, Jacen S Maier-Moore, Courtney G Montgomery, Nelson L Rhodus, A Darise Farris, Barbara M Segal, Roland Jonsson, Christopher J Lessard, R Hal Scofield, Kathy L Moser Sivils
• Extended report: Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study (6 September, 2013)

  R Landewé, J Braun, A Deodhar, M Dougados, W P Maksymowych, P J Mease, J D Reveille, M Rudwaleit, D van der Heijde, C Stach, B Hoepken, A Fichtner, G Coteur, M de Longueville, J Sieper
• Extended report: Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA) (13 August, 2013)

  P J Mease, R Fleischmann, A A Deodhar, J Wollenhaupt, M Khraishi, D Kielar, F Woltering, C Stach, B Hoepken, T Arledge, D van der Heijde
• Extended report: Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial (25 September, 2013)

  N P Quillinan, D McIntosh, J Vernes, S Haq, C P Denton
• Extended report: Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA) (4 October, 2013)

  Maxime Dougados, Martin Soubrier, Anna Antunez, Peter Balint, Alejandro Balsa, Maya H Buch, Gustavo Casado, Jacqueline Detert, Bassel El-zorkany, Paul Emery, Najia Hajjaj-Hassouni, Masayoshi Harigai, Shue-Fen Luo, Reka Kurucz, Gabriel Maciel, Emilio Martin Mola, Carlo Maurizio Montecucco, Iain McInnes, Helga Radner, Josef S Smolen, Yeong-Wook Song, Harald Erwin Vonkeman, Kevin Winthrop, Jonathan Kay
• Extended report: A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study) (31 July, 2013)

  Gerd R Burmester, Andrea Rubbert-Roth, Alain Cantagrel, Stephen Hall, Piotr Leszczynski, Daniel Feldman, Madura J Rangaraj, Georgia Roane, Charles Ludivico, Peng Lu, Lucy Rowell, Min Bao, Eduardo F Mysler
• Extended report: Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study) (2 August, 2013)

  J L Nam, E Villeneuve, E M A Hensor, P G Conaghan, H I Keen, M H Buch, A K Gough, M J Green, P S Helliwell, A M Keenan, A W Morgan, M Quinn, R Reece, D M van der Heijde, R J Wakefield, P Emery
• Extended report: Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial (20 August, 2013)

  Michael Schiff, Michael E Weinblatt, Robert Valente, Désirée van der Heijde, Gustavo Citera, Ayanbola Elegbe, Michael Maldonado, Roy Fleischmann
• Extended report: Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials (13 June, 2013)

  Joachim Sieper, Benjamin Porter-Brown, Liz Thompson, Olivier Harari, Maxime Dougados
• Extended report: Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1 (21 May, 2013)

  J Sieper, J Lenaerts, J Wollenhaupt, M Rudwaleit, V I Mazurov, L Myasoutova, S Park, Y Song, R Yao, D Chitkara, N Vastesaeger, on Behalf of All INFAST Investigators
• Extended report: Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2 (5 June, 2013)

  J Sieper, J Lenaerts, J Wollenhaupt, M Rudwaleit, V I Mazurov, L Myasoutova, S Park, Y Song, R Yao, D Chitkara, N Vastesaeger, on Behalf of All INFAST Investigators
• Extended report: Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review (16 April, 2013)

  Helga Radner, Tuhina Neogi, Josef S Smolen, Daniel Aletaha
• Extended report: Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study* (12 March, 2013)

  Iain B McInnes, Ho-Youn Kim, Sang-Heon Lee, David Mandel, Yeong-Wook Song, Carol A Connell, Zhen Luo, M Julia Brosnan, Andrea Zuckerman, Samuel H Zwillich, John D Bradley
• Extended report: The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study (3 January, 2013)

  Karen Minde Fagerli, Elisabeth Lie, Désirée van der Heijde, Marte Schrumpf Heiberg, Åse Stavland Lexberg, Eric Rødevand, Synøve Kalstad, Knut Mikkelsen, Tore K Kvien
• Extended report: Lymphoma risk in systemic lupus: effects of disease activity versus treatment (8 January, 2013)

  Sasha Bernatsky, Rosalind Ramsey-Goldman, Lawrence Joseph, Jean-Francois Boivin, Karen H Costenbader, Murray B Urowitz, Dafna D Gladman, Paul R Fortin, Ola Nived, Michelle A Petri, Soren Jacobsen, Susan Manzi, Ellen M Ginzler, David Isenberg, Anisur Rahman, Caroline Gordon, Guillermo Ruiz-Irastorza, Edward Yelin, Sang-Cheol Bae, Daniel J Wallace, Christine A Peschken, Mary Anne Dooley, Steven M Edworthy, Cynthia Aranow, Diane L Kamen, Juanita Romero-Diaz, Anca Askanase, Torsten Witte, Susan G Barr, Lindsey A Criswell, Gunnar K Sturfelt, Irene Blanco, Candace H Feldman, Lene Dreyer, Neha M Patel, Yvan St Pierre, Ann E Clarke
• Extended report: Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis (22 December, 2012)

  Sarah Louise Mackie, Elizabeth M A Hensor, Ann W Morgan, Colin T Pease
• Extended report: Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study (21 December, 2012)

  Alexis Ogdie, Kevin Haynes, Andrea B Troxel, Thorvardur Jon Love, Sean Hennessy, Hyon Choi, Joel M Gelfand
• Extended report: Annual direct medical cost of active systemic lupus erythematosus in five European countries (21 December, 2012)

  Andrea Doria, Zahir Amoura, Ricard Cervera, Munther A Khamastha, Matthias Schneider, Jutta Richter, Francis Guillemin, Gisela Kobelt, Frédérique Maurel, Anna Garofano, Alessandra Perna, Miranda Murray, Claude Schmitt, Isabelle Boucot
• Extended report: Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation (7 January, 2013)

  Bruce W Kirkham, Mary Chester Wasko, Elizabeth C Hsia, Roy M Fleischmann, Mark C Genovese, Eric L Matteson, Hongjuan Liu, Mahboob U Rahman
• Extended report:

  MicroRNA-146a and Ets-1 gene polymorphisms in ocular Behçet's disease and Vogt–Koyanagi–Harada syndrome

  (25 December, 2012)

  Qingyun Zhou, Shengping Hou, Liang Liang, Xinyu Li, Xiaoyu Tan, Lin Wei, Bo Lei, Aize Kijlstra, Peizeng Yang
• Extended report: Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout (12 January, 2013)

  Fernando Perez-Ruiz, Lorea Martínez-Indart, Loreto Carmona, Ana Maria Herrero-Beites, Jose Ignacio Pijoan, Eswar Krishnan
• Extended report: Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study (12 January, 2013)

  Daniel J Wallace, Kenneth Kalunian, Michelle A Petri, Vibeke Strand, Frederic A Houssiau, Marilyn Pike, Brian Kilgallen, Sabine Bongardt, Anna Barry, Lexy Kelley, Caroline Gordon
• Extended report: Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis (24 January, 2013)

  Jérôme Avouac, Dörte Huscher, Daniel E Furst, Christian F Opitz, Oliver Distler, Yannick Allanore, for the EPOSS group
• Extended report: Inequities in access to biologic and synthetic DMARDs across 46 European countries (6 March, 2013)

  Polina Putrik, Sofia Ramiro, Tore K Kvien, Tuulikki Sokka, Milena Pavlova, Till Uhlig, Annelies Boonen, Working Group ‘Equity in access to treatment of rheumatoid arthritis in Europe’
• Extended report: The characterisation and determinants of quality of life in ANCA associated vasculitis (25 January, 2013)

  Neil Basu, Andrew McClean, Lorraine Harper, Esther Nicole Amft, Neeraj Dhaun, Raashid A Luqmani, Mark A Little, David RW Jayne, Oliver Flossmann, John McLaren, Vinod Kumar, Lars P Erwig, David M Reid, Gareth T Jones, Gary J Macfarlane
• Extended report: International comparisons of the consultation prevalence of musculoskeletal conditions using population-based healthcare data from England and Sweden (23 January, 2013)

  Kelvin P Jordan, Anna Jöud, Charlotte Bergknut, Peter Croft, John J Edwards, George Peat, Ingemar F Petersson, Aleksandra Turkiewicz, Ross Wilkie, Martin Englund
• Extended report: Using lifestyle factors to identify individuals at higher risk of inflammatory polyarthritis (results from the European Prospective Investigation of Cancer-Norfolk and the Norfolk Arthritis Register—the EPIC-2-NOAR Study) (16 March, 2013)

  Manjari Lahiri, Robert N Luben, Catharine Morgan, Diane K Bunn, Tarnya Marshall, Mark Lunt, Suzanne M M Verstappen, Deborah P M Symmons, Kay-Tee Khaw, Nick Wareham, Ian N Bruce
• Extended report: Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients (19 February, 2013)

  Rohit Aggarwal, Elaine Cassidy, Noreen Fertig, Diane Carol Koontz, Mary Lucas, Dana P Ascherman, Chester V Oddis
• Concise report: Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol (13 August, 2013)

  D van der Heijde, R Fleischmann, J Wollenhaupt, A Deodhar, D Kielar, F Woltering, C Stach, B Hoepken, T Arledge, P J Mease
• Concise report: Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis (5 June, 2013)

  M M Schoels, J Braun, M Dougados, P Emery, O Fitzgerald, A Kavanaugh, T K Kvien, R Landewé, T Luger, P Mease, I Olivieri, J Reveille, C Ritchlin, M Rudwaleit, J Sieper, J S Smolen, M de Wit, D van der Heijde
• Concise report: Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial (26 April, 2013)

  H Haibel, C Fendler, J Listing, J Callhoff, J Braun, J Sieper
• Concise report: Correlations between nailfold microangiopathy severity, finger dermal thickness and fingertip blood perfusion in systemic sclerosis patients (3 May, 2013)

  A Sulli, B Ruaro, E Alessandri, C Pizzorni, M A Cimmino, G Zampogna, M Gallo, M Cutolo
• Concise report: The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA (5 May, 2013)

  Jakub Závada, Mark Lunt, Rebecca Davies, Audrey SL Low, Louise K Mercer, James B Galloway, Kath D Watson, Deborah P Symmons, Kimme L Hyrich, on behalf of the British Society for Rheumatology Biologics Register (BSRBR) Control Centre Consortium